Is Aduro Biotech (NASDAQ:ADRO) a Stock to Watch Now That Cowen \u0026 Co. Has Begun Covering It?

July 18, 2017 - By Winifred Garcia

 Is Aduro Biotech (NASDAQ:ADRO) a Stock to Watch Now That Cowen \u0026 Co. Has Begun Covering It?

How Cowen \u0026 Co. Currently Rates Aduro Biotech (NASDAQ:ADRO)

Cowen \u0026 Co. has started coverage on Aduro Biotech (NASDAQ:ADRO) shares recently in analysts note revealed to clients on Tuesday morning. The firm has decided to place a Outperform rating on ADRO stock.

Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage

Among 7 analysts covering Aduro Biotech (NASDAQ:ADRO), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Aduro Biotech has $68 highest and $14 lowest target. $33.17’s average target is 153.21% above currents $13.1 stock price. Aduro Biotech had 11 analyst reports since August 19, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, March 15 by Bank of America. The firm has “Outperform” rating given on Tuesday, October 20 by Oppenheimer. Roth Capital maintained it with “Buy” rating and $68 target in Tuesday, November 24 report. The rating was maintained by Roth Capital on Thursday, August 27 with “Buy”. Cowen & Co initiated the stock with “Buy” rating in Tuesday, July 18 report. The firm earned “Buy” rating on Tuesday, March 7 by Roth Capital. FBR Capital maintained it with “Outperform” rating and $22 target in Tuesday, May 17 report. The firm has “” rating by Leerink Swann given on Wednesday, August 19. The stock has “Buy” rating by TH Capital on Tuesday, November 24. The firm has “Perform” rating by Oppenheimer given on Tuesday, December 1.

It is down 1.22% since July 18, 2016 and is uptrending. It has underperformed by 15.48% the S&P500.

Analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to report $-0.41 EPS on August, 2.They anticipate $0.44 EPS change or 1,466.67 % from last quarter’s $0.03 EPS. After having $-0.32 EPS previously, Aduro BioTech Inc’s analysts see 28.13 % EPS growth.

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The company has market cap of $944.71 million. The Company’s product candidates from its Live, Attenuated, Double-Deleted Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. It currently has negative earnings. The Company’s LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers.

More recent Aduro BioTech Inc (NASDAQ:ADRO) news were published by: which released: “Aduro Biotech to Present at Two Investor Conferences in March” on February 28, 2017. Also published the news titled: “Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in …” on June 29, 2017.‘s news article titled: “Aduro Biotech (ADRO) Earns $2M Milestone Payment Relating to Collaboration …” with publication date: July 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.